## Louis Dubeau

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/830996/publications.pdf

Version: 2024-02-01

29 2,222 18 27
papers citations h-index g-index

29 29 29 3519 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metabolism, 2015, 22, 86-99.	7.2	635
2	The cell of origin of ovarian epithelial tumours. Lancet Oncology, The, 2008, 9, 1191-1197.	5.1	323
3	The Cell of Origin of Ovarian Epithelial Tumors and the Ovarian Surface Epithelium Dogma: Does the Emperor Have No Clothes?. Gynecologic Oncology, 1999, 72, 437-442.	0.6	240
4	Cell-Nonautonomous Induction of Ovarian and Uterine Serous Cystadenomas in Mice Lacking a Functional Brca1 in Ovarian Granulosa Cells. Current Biology, 2005, 15, 561-565.	1.8	226
5	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. Genome Medicine, 2015, 7, 108.	3.6	138
6	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncology, The, 2013, 14, 1226-1232.	5.1	98
7	Maf1 Is a Novel Target of PTEN and PI3K Signaling That Negatively Regulates Oncogenesis and Lipid Metabolism. PLoS Genetics, 2014, 10, e1004789.	1.5	77
8	Pathogenesis of serous, extra-uterine $M\tilde{A}\frac{1}{4}$ llerian epithelial cancer and therapeutic implications. Translational Cancer Research, 2015, 4, 3-13.	0.4	57
9	Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. Nature Communications, 2016, 7, 11620.	5.8	56
10	Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine, 2015, 2, 1331-1339.	2.7	49
11	Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget, 2017, 8, 3811-3825.	0.8	45
12	Changes in the Mouse Estrus Cycle in Response to Brca1 Inactivation Suggest a Potential Link between Risk Factors for Familial and Sporadic Ovarian Cancer. Cancer Research, 2010, 70, 221-228.	0.4	40
13	GRP78 haploinsufficiency suppresses acinar-to-ductal metaplasia, signaling, and mutant <i>Kras</i> driven pancreatic tumorigenesis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4020-E4029.	3.3	39
14	Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. Oncotarget, 2017, 8, 103543-103556.	0.8	39
15	Aneuploidy and telomere attrition are independent determinants of crisis in SV40-transformed epithelial cells. Cancer Research, 2003, 63, 5813-20.	0.4	23
16	Epigenetic regulation of AXL and risk of childhood asthma symptoms. Clinical Epigenetics, 2017, 9, 121.	1.8	22
17	Establishment of Long-Termin VitroCultures of Human Ovarian Cystadenomas and LMP Tumors and Examination of Their Spectrum of Expression of Matrix-Degrading Proteinases. Gynecologic Oncology, 1997, 67, 277-284.	0.6	21
18	Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs. Laboratory Investigation, 2012, 92, 802-811.	1.7	20

#	Article	IF	CITATIONS
19	Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma. Scientific Reports, 2020, 10, 2160.	1.6	20
20	Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells. International Journal of Cancer, 2012, 130, 2495-2504.	2.3	16
21	Glucose-regulated protein 94 deficiency induces squamous cell metaplasia and suppresses PTEN-null driven endometrial epithelial tumor development. Oncotarget, 2016, 7, 14885-14897.	0.8	9
22	A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State. EBioMedicine, 2015, 2, 1318-1330.	2.7	8
23	Association between <i>AXL</i> promoter methylation and lung function growth during adolescence. Epigenetics, 2018, 13, 1027-1038.	1.3	6
24	Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways. International Journal of Cancer, 2018, 143, 2932-2942.	2.3	6
25	Non-Surgical Cancer Risk Reduction in BRCA1 Mutation Carriers: Disabling the Remote Control. Cancers, 2020, 12, 547.	1.7	3
26	A Phosphotyrosine Switch in Estrogen Receptor $\hat{l}^2$ Is Required for Mouse Ovarian Function. Frontiers in Cell and Developmental Biology, 2021, 9, 649087.	1.8	3
27	Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent. PLoS ONE, 2015, 10, e0139013.	1.1	3
28	First reported case of BRAF V600E mutation in Tâ€eell prolymphocytic leukaemia. British Journal of Haematology, 2020, 191, e52-e55.	1.2	0
29	Molecular testing in Gynecological Malignancies. , 2014, , 229-241.		O